Avenue Therapeutics, Inc. (ATXI) Stock Price, Quote, News & Analysis
Entering text into the input field will update the search result below
Search for Symbols, analysts, keywords

ATXI Avenue Therapeutics, Inc.
Stock Price & Overview

$4.51-6.35 (-58.46%)4:00 PM 04/29/24
NASDAQ | $USD | Post-Market: $4.49 -0.03 (-0.59%) 7:58 PM

Charts

52 Week Range
4.51
93.75
Day Range
4.51
5.35
EPS (FWD)
-30.75
PE
-
Div Rate
-
Yield
-
Market Cap
$3.66M
Volume
231,710
Prev. Close
$10.87
Expand For Key Data »

Quant Ranking

ATXI Analysis

ATXI News

See All News »

Latest Headlines

Ratings Summary

People Also Follow

Compare

Similar to ATXI

SymbolLast PriceChange
VRPX
0
0.00%
Virpax Pharmaceuticals, Inc.
SNES
0
0.00%
SenesTech, Inc.
APLIF
0
0.00%
Appili Therapeutics Inc.
CYTO
0
0.00%
Altamira Therapeutics Ltd.
EVOK
0
0.00%
Evoke Pharma, Inc.
Compare

ETFs Holding ATXI

SymbolLast PriceChange
VEMPXVanguard Extended Market Index Fund Inst
0
0.00%
0.00%

ATXI Company Profile

Avenue Therapeutics, Inc. logo
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Sector
Health Care
Industry
Pharmaceuticals
Employees
3
Founded
2015
Address
  • 1111 Kane Concourse
  • Suite 301
  • Bay Harbor Islands, FL, 33154
  • United States
Phone Number
781 652 4500
Website
www.avenuetx.com
Hide

ATXI Revenue

More On Revenue »

ATXI Earnings Per Share

More On Earnings »

Earnings Estimates

FY
EPS
YoY
PE
Sales
YoY
2024
-30.75
+58.16%
-0.15
$0.00
-
2025
-27.75
+9.76%
-0.16
$0.00
-
2026
-33.00
-18.92%
-0.14
$0.00
-
More On Earnings Estimates »

Earnings Revisions

Rating:
FY1 Up Revisions
0
FY1 Down Revisions
0
100% Down0% Up
More On Earnings Revisions »

Valuation

Rating:
P/E Non-GAAP (FWD)
-
P/E GAAP (TTM)
NM
Price/Book (TTM)
1.34
EV/Sales (TTM)
-
EV/EBITDA (TTM)
-
More On Valuation »

Profitability

Rating:
Gross Profit Margin
-
EBIT Margin
-
Net Income Margin
-
Return on Equity
-535.10%
Return on Assets
-560.92%
More On Profitability »

Momentum

Rating:
Ticker
3M
6M
9M
1Y
ATXI
-44.89%
-76.31%
-92.35%
-90.92%
SP500
+4.27%
+23.27%
+11.68%
+25.74%

52 Week Range

5.78
Last price: 4.5147
93.75
More On Momentum »

Capital Structure

Market Cap
$3.66M
Total Debt
$0.00
Cash
$1.78M
Other
-
Enterprise Value
$947.87K

Trading Data

Volume
231,710
Average Volume (3 months)
27,729
Previous Close
10.87
Open
5.07
Shares Outstanding (Ticker)
590,140

Dividends

ATXI does not currently pay a dividend.

ATXI Ownership

Type
Common Stock Held
% of Shares Outstanding
Market Value
Composition
Institutions
16,394
2.78%
74,014
Corporations (Public)
47,298
8.01%
213,536
Corporations (Private)
90
0.02%
406
Individuals / Insiders
22,417
3.80%
101,206
Public and Other
503,941
85.39%
2.28M
Total
590,140
100.00%
2.66M

ATXI Peers

Title
VRPXSNESAPLIFCYTO
Company name
Virpax Pharmaceuticals, Inc.
SenesTech, Inc.
Appili Therapeutics Inc.
Altamira Therapeutics Ltd.
Industry
PharmaceuticalsPharmaceuticalsPharmaceuticalsPharmaceuticals
Market Cap
3.63M
3.75M
3.55M
3.79M
Employees
7
25
9
10

Go Premium to see ratings on ATXI peers.

More On Peers »

Risk

24M Beta
-1.02
Altman Z Score
-

Technicals

Title
10D SMA
50D SMA
200D SMA
Simple Moving Average
9.11
11.08
31.26
Last Price vs SMA
-31.92%
-44.06%
-80.17%
More On Moving Averages »

ATXI Transcripts

Investor Presentations

ATXI SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

ATXI Income Statement

Revenue (TTM)
-
Revenue Per Share
-
Gross Profit (TTM)
-
EBITDA (TTM)
-
Net Income (TTM)
-10.38M
EPS Diluted (TTM)
-$73.48
Full Income Statement »

ATXI Balance Sheet

Total Cash (MRQ)
1.78M
Total Cash Per Share
5.22
Total Debt (MRQ)
0.00
Total Debt to Equity (MRQ)
-
Current Ratio (MRQ)
1.55
Quick Ratio (MRQ)
1.49
Full Balance Sheet »

ATXI Cash Flow Statement

Cash from Operations (TTM)
-9.45M
Cash from Investing (TTM)
-3.00M
Levered Free Cash Flow (TTM)
-13.49M
Unlevered Free Cash Flow (TTM)
-13.49M
Free Cash Flow / Share (TTM)
-$88.17
Full Cash Flow Statement »

ATXI Long Term Solvency

Total Debt / Equity (MRQ)
-
Total Debt / Capital (MRQ)
-
LT Debt / Equity (MRQ)
-
LT Debt / Total Capital (MRQ)
-
Total Liabilities / Total Assets (MRQ)
64.65

Discover More

You may be interested in:

People Also Follow

Compare

Similar to ATXI

SymbolLast PriceChange
VRPX
0
0.00%
Virpax Pharmaceuticals, Inc.
SNES
0
0.00%
SenesTech, Inc.
APLIF
0
0.00%
Appili Therapeutics Inc.
CYTO
0
0.00%
Altamira Therapeutics Ltd.
EVOK
0
0.00%
Evoke Pharma, Inc.
Compare

ETFs Holding ATXI

SymbolLast PriceChange
VEMPXVanguard Extended Market Index Fund Inst
0
0.00%
0.00%